🇺🇸 FDA
Patent

US 10813909

Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

granted A61KA61K31/155A61K31/337

Quick answer

US patent 10813909 (Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer) held by The Regents of the University of California expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/155, A61K31/337, A61K31/351, A61K31/366